31st March 2025 Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek reported FY25 revenue from operations of Rs 26.07 lakhs, up from Rs 23.49 lakhs in FY24, with total income of Rs 104.42 lakhs boosted by other income of Rs 78.35 lakhs. However, total expenses surged to Rs 172.03 lakhs (vs Rs 107.30 lakhs), led by sharply higher other expenses and finance costs, resulting in a net loss of Rs 67.61 lakhs, slightly worse than the Rs 65.55 lakh loss last year. The Q4 standalone loss widened sharply to Rs 71.31 lakhs from Rs 27.23 lakhs. EPS stood at Rs (0.09). The auditor (Vasavi & Co) issued an unmodified opinion. The company disclosed an Enforcement Directorate order dated 30 December 2024 imposing a Rs 203.02 crore penalty under FEMA 2000 over an old GDR issue, which the company is challenging at the Securities Appellate Tribunal (next hearing noted in July 2025). The standalone balance sheet shows negative other equity of Rs -8,333.75 lakhs, making net worth negative at Rs -756.75 lakhs. The Hong Kong subsidiary has not been audited for years and its books are carried forward from FY16.
Shareholders face a very risky setup: standalone net worth is negative, the ED penalty of ~Rs 203 Cr is several times the company's total assets (Rs 34 Cr), and accumulated losses are mounting — any adverse SAT ruling could be existential. The marginally higher revenue and positive operating cash flow of Rs 119.58 lakhs offer small comfort, but the stock remains a high-risk, speculative bet pending the FEMA appeal outcome.